A pharmaceutical composition and method for therapy of neurodegenerative diseases including amyotrophic lateral sclerosis, the composition comprising an adenoviral vector, expressing a human angiogenesis factor gene an effective amount of the adenoviral vector in the form of a non-replicating nanoparticle based on a genome of human adenovirus type 5 with an insertion of a human angiogenin gene which produces the human angiogenesis in a human body a non-replicating nanoparticle based on the genome of human adenovirus type 5 with an insertion of a human vascular endothelium growth factor gene and a formulating buffer wherein the human angiogenin factor gene and the human vascular endothelium growth factor gene are cloned in two expression cassettes within one non-replicating nanoparticle based on the genome of human adenovirus type 5.
